Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients

Metabolism: Clinical and Experimental

Volumn 63, Issue 6, 2014, Pages 746-753

  Imai, Chihiro ^a   Saito, Miyoko ^b   Mochizuki, Kazuki ^c   Fuchigami, Masahiro ^d   Goda, Toshinao ^a   Osonoi, Takeshi ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Naka Kinen Clinic   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

Author keywords

Adhesion molecule; Combination therapy; CVD risk factor; Inflammatory cytokine; Type 2 diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; ALBUMIN; CREATININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOALBUMIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MIGLITOL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMA PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SITAGLIPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIABETIC PATIENT; EXPLORATORY RESEARCH; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; JAPANESE (PEOPLE); MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK REDUCTION; TEST MEAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADHESION MOLECULE; COMBINATION THERAPY; CVD RISK FACTOR; INFLAMMATORY CYTOKINE; TYPE 2 DIABETES;

1-DEOXYNOJIRIMYCIN; ADULT; AGED; ALPHA-GLUCOSIDASES; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; E-SELECTIN; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INTERLEUKIN-8; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRAZINES; RISK FACTORS; TRIAZOLES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84901245181     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.12.014     Document Type: Article

References (29)

1. D. Giugliano, A. Ceriello, and K. Esposito Glucose metabolism and hyperglycemia Am J Clin Nutr 87 2008 217S 222S
2. J.L. Chiasson, R.G. Josse, and R. Gomis et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494
3. U. Zeymer, A. Schwarzmaier-D'assie, and D. Petzinna et al. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy Eur J Cardiovasc Prev Rehabil 11 2004 412 415
4. M. Hanefeld, M. Cagatay, and T. Petrowitsch et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 25 2004 10 16
5. T. Goda, K. Suruga, and A. Komori et al. Effects of miglitol, an α-glucosidase inhibitor, on glycaemic status and histopathological changes in islets in non-obese, non-insulin-dependent diabetic Goto-Kakizaki rats Br J Nutr 98 2007 702 710
6. M. Arakawa, C. Ebato, and T. Mita et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects Metabolism 57 2008 1299 1306
7. T. Osonoi, M. Saito, and K. Mochizuki et al. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus Metabolism 59 2010 1816 1822
8. S. Mudaliar, and R.R. Henry Effects of incretin hormones on β-cell mass and function, body weight, and hepatic and myocardial function Am J Med 123 2010 S19 S27
9. B.J. Zarowitz, and C. Conner The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus Pharmacotherapy 29 2009 55S 67S
10. E. Demerath, B. Towne, and J. Blangero et al. The relationship of soluble ICAM-1, VCAM-1, P-selectin and E-selectin to cardiovascular disease risk factors in healthy men and women Ann Hum Biol 28 2001 664 678
11. H. Hattori, H. Sato, and D. Ito et al. A561C polymorphism of E-selectin is associated with ischemic cerebrovascular disease in the Japanese population without diabetes mellitus and hypercholesterolemia Brain Res 1108 2006 221 223
12. S.S. Soedamah-Muthu, N. Chaturvedi, and C.G. Schalkwijk et al. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in type 1 diabetic patients J Diabetes Complications 20 2006 188 195
13. A. Miyachi, T. Murase, and Y. Yamada et al. Quantitative analytical method for determining the levels of gastric inhibitory polypeptides GIP1-42 and GIP3-42 in human plasma using LC-MS/MS/MS J Proteome Res 12 2013 2690 2699
14. K. Aoki, K. Masuda, and T. Miyazaki et al. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men Endocr J 57 2010 667 672
15. M. Kishimoto, and M. Noda A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers Cardiovasc Diabetol 10 2011 115
16. T. Kawasaki, T. Yamanouchi, and A. Kashiwabara et al. The influence of traditional Chinese herbal drugs on serum 1, 5-anhydroglucitol levels Diabetes Res Clin Pract 50 2000 97 101
17. D. Gentilcore, B. Bryant, and J.M. Wishart et al. Acarbose attenuates the hypotensive response to sucrose and slows gastric emptying in the elderly Am J Med 118 2005 1289
18. A. Lee, P. Patrick, and J. Wishart et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics Diabetes Obes Metab 4 2002 329 335
19. K. Aoki, T. Miyazaki, and J. Nagakura et al. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men Endocr J 57 2010 673 677
20. L. Van Gaal, M. Maislos, and G. Schernthaner et al. Miglitol combined with metformin improves glycaemic control in type 2 diabetes Diabetes Obes Metab 3 2001 326 331
21. 2 + channel-dependent exocytosis Cell Metab 11 2010 543 553
22. O.G. Kolterman, J.B. Buse, and M.S. Fineman et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes J Clin Endocrinol Metab 88 2003 3082 3089
23. T.P. Zerilli, and E.Y. yon Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus Clin Ther 29 2007 2614 2634
24. A.E. Caballero, A. Delgado, and C.A. Aguilar-Salinas et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial J Clin Endocrinol Metab 89 2004 3943 3948
25. J. De Jager, A. Kooy, and P. Lehert et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial J Intern Med 257 2005 100 109
26. B. Hemmingsen, S.S. Lund, and J. Wetterslev et al. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes Eur J Endocrinol 161 2009 1 9
27. G.A. Herman, G.C. Mistry, and B. Yi et al. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males Br J Clin Pharmacol 71 2011 429 436
28. Y. Kato, H. Narita, and H. Suzuki et al. Voglibose, an α-glucosidase inhibitor, dose not affect the pharmacokinetics and pharmacodynamics of sitagliptin, a DPP-4 inhibitor Diabetes 58 Suppl 1 2009 A164
29. G.I. Uwaifo, and R.E. Ratner Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk Am J Cardiol 99 2007 51B 67B